All In MedTech

Device Trial Radar · NCT03090633

Fetoscopic Repair of Isolated Fetal Spina Bifida

Study of Fetoscopic Repair of Myelomeningocele in Fetuses With Isolated Spina Bifida

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 11, 2017

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 27, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this investigation is to evaluate maternal and fetal outcomes following fetoscopic repair of fetal spina bifida at the Johns Hopkins Hospital. The hypothesis of this study is that fetoscopic spina bifida repair is feasible and has the same effectiveness as open repair of fetal spina bifida, but with the benefit of significantly lower maternal and fetal complication rates. The fetal benefit of the procedure will be the prenatal repair of spina bifida. The maternal benefit of fetoscopic spina bifida repair will be the avoidance of a large uterine incision. This type of incision increases the risk of uterine rupture and requires that all future deliveries are by cesarean section. The use of the minimally invasive fetoscopic surgical technique may also lower the risk of preterm premature rupture of membranes and preterm birth compared to open fetal surgery. Finally, successful fetoscopic spina bifida repair also makes vaginal delivery possible.

Conditions

  • Spina Bifida
  • Myelomeningocele
  • Chiari Malformation Type 2
  • Neural Tube Defects
  • Spinal Dysraphism
  • Congenital Abnormality

Interventions

  • FetoscopyDevice

    Minimally invasive in-utero surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ability to perform fetoscopic spina bifida repairTime frame: From time of surgery until delivery (up to 21 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.